Patent: 10,095,829
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Summary for Patent: 10,095,829
Title: | Computer implemented methods of treating lung cancer |
Abstract: | The present invention concerns a method for predicting the relative efficacy of a plurality of drugs for treating a tumor in an individual comprising the molecular characterization of the tumor, and the calculation of a score for the plurality of drugs essentially based on the percentage of deregulated target genes. |
Inventor(s): | Lazar; Vladimir (Villejuif, FR), Soria; Jean-Charles (Igny, FR), Ducreux; Michel (Vanves, FR), Tursz; Thomas (Paris, FR) |
Assignee: | WORLDWIDE INNOVATIVE NETWORK (Villejuif, FR) |
Application Number: | 13/382,585 |
Patent Claims: | see list of patent claims |
Details for Patent 10,095,829
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | See Plans and Pricing | 2029-07-08 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | See Plans and Pricing | 2029-07-08 |
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 02/12/2004 | See Plans and Pricing | 2029-07-08 |
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 03/28/2007 | See Plans and Pricing | 2029-07-08 |
Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | 02/26/2004 | See Plans and Pricing | 2029-07-08 |
Genentech, Inc. | HERCEPTIN HYLECTA | trastuzumab and hyaluronidase-oysk | Injection | 761106 | 02/28/2019 | See Plans and Pricing | 2029-07-08 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |